Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma

Assiut University1 site in 1 country68 target enrollmentMay 1, 2022

ConditionsGastric Carcinoma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Gastric Carcinoma
Sponsor: Assiut University
Enrollment: 68
Locations: 1
Primary Endpoint: Difference in DNMT1 and EZH2 expression.
Status: Recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The goal of this cross-sectional study is to evaluate epigenetic modifications in gastric carcinogenesis, mainly in H. pylori gastritis vs gastric carcinoma. The main question[s] it aims to answer are:

How does H. pylori infection cause gastric cancer?
Can DNA methylation and other epigenetic changes predict and affect the development of gastric cancer? Formalin-fixed-paraffin-embedded tissue specimens will be obtained and reviewed for comparison between epigenetic changes in H. pylori gastritis and gastric adenocarcinoma.

Registry

clinicaltrials.gov

Start Date

May 1, 2022

End Date

December 31, 2024

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Assiut University

Responsible Party

Principal Investigator

Aliyah Soliman Ali

Pathology resident

Assiut University

Eligibility Criteria

Inclusion Criteria

•Resected specimens and endoscopic guided biopsies of intestinal type gastric carcinoma, H. Pylori associated gastritis, and non-H. Pylori gastritis with:
•Available full clinical data: (age, sex, complaint, findings in clinical examination).
•Full data of previous endoscopy and radiology.

Exclusion Criteria

•Cases of diffuse type gastric carcinoma.
•Any case of gastric cancer, H. Pylori associated gastritis, non-H. Pylori gastritis, benign gastric lesions with missing clinical, endoscopic, radiologic or follow-up data.
•Cases with no available H\&E stained slides or formalin fixed paraffin embedded block.

Outcomes

Primary Outcomes

Difference in DNMT1 and EZH2 expression.

Time Frame: two years

Histopathological evaluation of routine H\&E slides and immunohistochemical markers to compare the intensity and extent of epigenetic changes in both H. Pylori associated gastritis and gastric carcinoma.